Table of Contents

company-logo

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Inhibikase Therapeutics Dividend Announcement

• Inhibikase Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Inhibikase Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Inhibikase Therapeutics Dividend History

Inhibikase Therapeutics Dividend Yield

Inhibikase Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Inhibikase Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Inhibikase Therapeutics Financial Ratios

P/E ratio-1.06
PEG ratio0.02
P/B ratio-39.17
ROE-350.62%
Payout ratio0.00%
Current ratio0.85
Quick ratio0.85
Cash Ratio0.19

Inhibikase Therapeutics Dividend FAQ

Does Inhibikase Therapeutics stock pay dividends?
Inhibikase Therapeutics does not currently pay dividends to its shareholders.
Has Inhibikase Therapeutics ever paid a dividend?
No, Inhibikase Therapeutics has no a history of paying dividends to its shareholders. Inhibikase Therapeutics is not known for its dividend payments.
Why doesn't Inhibikase Therapeutics pay dividends?
There are several potential reasons why Inhibikase Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Inhibikase Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Inhibikase Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Inhibikase Therapeutics a dividend aristocrat?
Inhibikase Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Inhibikase Therapeutics a dividend king?
Inhibikase Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Inhibikase Therapeutics a dividend stock?
No, Inhibikase Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Inhibikase Therapeutics stocks?
To buy Inhibikase Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Inhibikase Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.